Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06805474 · ClinicalTrials.gov registry record
A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT
A clinical trial of Geographic Atrophy and Macular Degeneration, sponsored by Nanoscope Therapeutics.
- Recruiting
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT06805474 is a study of Geographic Atrophy and Macular Degeneration that is actively recruiting participants, run by Nanoscope Therapeutics. The registered enrollment target is 30 participants, below the 221-participant average among 27 other Geographic Atrophy trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06805474, a study of Geographic Atrophy and Macular Degeneration, is actively recruiting participants, sponsored by Nanoscope Therapeutics.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this observational study is to assess the reliability and validity of the 9-object MLSDT for evaluation of participants with moderate to severe vision impairment when tested without a wearable low-vision magnifying aid (eGlasses) and then with eGlasses. These results will be compared to ETDRS testing results for the same participants without eGlasses and then with eGlasses. Two cohorts will consist of participants who have vision loss due to STGD or geographic atrophy (GA) due to age-related macular degenerations (AMD). Normally sighted participants will provide a control group.
Conditions Studied
Interventions
- OTHER Observational
Study Locations (1)
Texas
- Retina of North Texas, - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-01-28 |
| Est. Completion | 2025-05-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06805474
The ClinicalTrials.gov registry entry for NCT06805474 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 27 other Geographic Atrophy trials with a reported enrollment target (86% lower). The listed sponsor is Nanoscope Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Geographic Atrophy appearing as the primary indexed condition, and to 1 intervention - of which Observational is the first listed.
NCT06805474 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06805474 about?
NCT06805474 is a clinical study titled "A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT". The goal of this observational study is to assess the reliability and validity of the 9-object MLSDT for evaluation of participants with moderate to severe vision impairment when tested without a wearable low-vision magnifying aid (eGlasses) and then with eGlasses. These results will be compared to ...
What is the current status of trial NCT06805474?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2025-01-28. Estimated completion is 2025-05-27.
What conditions does trial NCT06805474 study?
This clinical trial studies the following conditions: Geographic Atrophy, Macular Degeneration, Stargardt Disease.
What interventions are being tested in trial NCT06805474?
The interventions under investigation include: Observational (OTHER).
Who is sponsoring clinical trial NCT06805474?
This trial is sponsored by Nanoscope Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06805474 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Geographic Atrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
RECRUITING · Phase 1
-
High Resolution Retinal Imaging
RECRUITING
-
SGLT2 Inhibitors in Geographic Atrophy
RECRUITING · Phase 2
-
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RECRUITING · Phase 2
-
A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)
RECRUITING · Phase 2
-
Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.